Healthcare / Diagnostics & ResearchNSE
$281.70
-3.80 (-1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $150.1M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.7B
P/E
45.7x
↑EV/EBITDA
16.2x
↑ROE
13.1%
↑Gross Margin
88.2%
↑Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+17.7%
FCF CAGR
-22.3%
FCF margin
4.7%
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.10B · net income $321.9M · FCF $144.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.10B | $3.10B | $2.52B | $2.19B | $1.90B |
| Net Income | $321.9M | $321.9M | $318.2M | $236.3M | $65.2M |
| EBITDA | $985.6M | $985.6M | $850.9M | $728.4M | $474.8M |
| EPS | — | — | 5.97 | 4.54 | 1.25 |
| Gross Margin | 88.2% | 88.2% | 88.3% | 87.5% | 85.6% |
| Operating Margin | 17.5% | 17.5% | 19.1% | 18.7% | 8.3% |
| Net Margin | 10.4% | 10.4% | 12.6% | 10.8% | 3.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.42 | 0.50 | 0.62 |
| Current Ratio | 1.05 | 1.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $144.8M | $144.8M | $213.4M | $150.1M | $309.3M |
| Returns | |||||
| ROE | 13.1% | 13.1% | 15.1% | 13.2% | 4.2% |
| Valuation | |||||
| P/E | 45.66 | 45.66 | 47.09 | — | — |
| EV/EBITDA | 16.18 | 16.18 | 18.63 | — | — |
| P/B | 5.99 | 5.99 | 7.09 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 23.1% | 23.1% | 15.3% | 15.0% | — |
| EPS Growth | — | — | 31.6% | 262.6% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.6%
Start / end P/E
n/dx → n/dx
EPS bridge
5.97 → n/d
Residual
-12.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.